These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15172014)

  • 1. Identification and measurement of genomic biomarkers of nephrotoxicity.
    Goodsaid FM
    J Pharmacol Toxicol Methods; 2004; 49(3):183-6. PubMed ID: 15172014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of putative genomic biomarkers of nephrotoxicity in rats.
    Wang EJ; Snyder RD; Fielden MR; Smith RJ; Gu YZ
    Toxicology; 2008 Apr; 246(2-3):91-100. PubMed ID: 18289764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic-based biomarkers of drug-induced nephrotoxicity.
    Davis JW; Kramer JA
    Expert Opin Drug Metab Toxicol; 2006 Feb; 2(1):95-101. PubMed ID: 16863471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical perspective of urinary biomarkers for the detection of nephrotoxicity: what we know and what we need to know.
    Fuchs TC; Hewitt P
    Biomark Med; 2011 Dec; 5(6):763-79. PubMed ID: 22103611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in diagnosing acute calcineurin-inhibitor induced nephrotoxicity: from toxicogenomics to emerging biomarkers.
    Pallet N; Djamali A; Legendre C
    Pharmacol Res; 2011 Jul; 64(1):25-30. PubMed ID: 21473913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future of toxicogenomics and safety signatures: balancing public access to data with proprietary drug discovery.
    Fostel JM
    Pharmacogenomics; 2007 May; 8(5):425-30. PubMed ID: 17465705
    [No Abstract]   [Full Text] [Related]  

  • 7. Identification of potential genomic biomarkers of hepatotoxicity caused by reactive metabolites of N-methylformamide: Application of stable isotope labeled compounds in toxicogenomic studies.
    Mutlib A; Jiang P; Atherton J; Obert L; Kostrubsky S; Madore S; Nelson S
    Chem Res Toxicol; 2006 Oct; 19(10):1270-83. PubMed ID: 17040096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring kidney safety in drug development: emerging technologies and their implications.
    Dieterle F; Marrer E; Suzuki E; Grenet O; Cordier A; Vonderscher J
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):60-71. PubMed ID: 18175268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety biomarkers in preclinical development: translational potential.
    Sasseville VG; Mansfield KG; Brees DJ
    Vet Pathol; 2014 Jan; 51(1):281-91. PubMed ID: 24091814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of genomic biomarkers for concurrent diagnosis of drug-induced renal tubular injury using a large-scale toxicogenomics database.
    Kondo C; Minowa Y; Uehara T; Okuno Y; Nakatsu N; Ono A; Maruyama T; Kato I; Yamate J; Yamada H; Ohno Y; Urushidani T
    Toxicology; 2009 Nov; 265(1-2):15-26. PubMed ID: 19761811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicogenomics in drug discovery and development: mechanistic analysis of compound/class-dependent effects using the DrugMatrix database.
    Ganter B; Snyder RD; Halbert DN; Lee MD
    Pharmacogenomics; 2006 Oct; 7(7):1025-44. PubMed ID: 17054413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic and proteomic profiling for biomarkers and signature profiles of toxicity.
    Merrick BA; Bruno ME
    Curr Opin Mol Ther; 2004 Dec; 6(6):600-7. PubMed ID: 15663324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel biomarkers of acute kidney toxicity.
    Goodsaid FM; Blank M; Dieterle F; Harlow P; Hausner E; Sistare F; Thompson A; Vonderscher J
    Clin Pharmacol Ther; 2009 Nov; 86(5):490-6. PubMed ID: 19710639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicogenomics in drug discovery: from preclinical studies to clinical trials.
    Yang Y; Blomme EA; Waring JF
    Chem Biol Interact; 2004 Nov; 150(1):71-85. PubMed ID: 15522262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Qualified kidney biomarkers and their potential significance in drug safety evaluation and prediction.
    Xie HG; Wang SK; Cao CC; Harpur E
    Pharmacol Ther; 2013 Jan; 137(1):100-7. PubMed ID: 23017937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The state-of-the-art in predictive toxicogenomics.
    Fielden MR; Kolaja KL
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):84-91. PubMed ID: 16445120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced nephrotoxicity: clinical impact and preclinical in vitro models.
    Tiong HY; Huang P; Xiong S; Li Y; Vathsala A; Zink D
    Mol Pharm; 2014 Jul; 11(7):1933-48. PubMed ID: 24502545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers.
    Thukral SK; Nordone PJ; Hu R; Sullivan L; Galambos E; Fitzpatrick VD; Healy L; Bass MB; Cosenza ME; Afshari CA
    Toxicol Pathol; 2005; 33(3):343-55. PubMed ID: 15805072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic and proteomic approaches for predicting toxicity and adverse drug reactions.
    Ge F; He QY
    Expert Opin Drug Metab Toxicol; 2009 Jan; 5(1):29-37. PubMed ID: 19236227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicologic Pathology Forum Opinion Paper*: Recommendations for a Tiered Approach to Nonclinical Mechanistic Nephrotoxicity Evaluation.
    Ennulat D; Ringenberg M; Frazier KS
    Toxicol Pathol; 2018 Aug; 46(6):636-646. PubMed ID: 30049250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.